NAUTIKA1: Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 125 patients (estimated)
- Sponsors
- Genentech, Tyligand Bioscience
- Collaborators
- Blueprint Medicines
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1713
- NCT Identifier
- NCT04302025
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.